Spectrofluorimetric Method for Determination of Letrozole: Analytical Applications to Brain Tissue Samples and Alkaline Degradation Kinetic Study
- 3 Downloads
A simple and sensitive spectroflourimetric method has been proposed for the determination of the antitumor agent letrozole in tablets, spiked human plasma, and rat brain tissue homogenates. Our method involves measuring the native fluorescence of letrozole at 590 nm upon excitation at 239 nm as indicated upon scanning its three-dimensional spectrum. Various experimental parameters were intensively studied and the method was validated as per ICH guidelines. The calibration curve was linear over the concentration range 5–160 ng/mL, with limit of detection 1.36 ng/mL. It was successfully applied to the analysis of letrozole in Femara® tablets with mean recovery 99.35 ± 1.49% and was further applied to study the alkaline degradation kinetics of letrozole. The pseudo first-order rate constant and half-life were calculated. Moreover, successful application of our proposed procedure was carried out on spiked human plasma and rat brain tissue samples. Linear ranges were found to be 5–30 and 10–130 ng/mL, with detection limits 1.25 and 1.71 ng/mL for plasma and brain samples, respectively. Thanks to the method's simplicity, selectivity, and high sensitivity, it can be used for routine analysis in quality control laboratories and for further clinical investigations involving letrozole.
Keywordsletrozole spectrofluorimetry gliomas rate constant half-life
Unable to display preview. Download preview PDF.
- 1.M. Sittig, Pharmaceutical Manufacturing Encyclopedia Textbook, 3rd ed., William Andrew Publishing, Norwich, New York (2013).Google Scholar
- 9.N. Mondal, T. K. Pal, and S. K. Ghosal, Pharmazie, 62, 597–598 (2007).Google Scholar
- 10.M. Ganesh, K. Kamalakannan, R. Patil, S. Upadhyay, A. Srivatsava, T. Sivakumar, and S. Ganguly, Rasayan J. Chem., 1, 55–58 (2008).Google Scholar
- 13.C. U. Pfister, M. Duval, J. Godbillon, G. Gosset, D. Gygax, F. Marfil, A. Sioufi , and B. Winkler, Int. J. Pharm. Sci., 83, 520–524 (1994).Google Scholar
- 14.N. Mondal, T. K. Pal, and S. K. Ghosal, Acta Pol. Pharm., 66, 11–17 (2009).Google Scholar
- 17.A. Shrivastava, A. K. Chakraborty, S. K. Rambhade, and U. K. Patil, Pharm. Sin., 2, 263–269 (2011).Google Scholar
- 20.F. Marfil, V. Pineau, A. Sioufi , and J. Godbillon, J. Chromatogr. B, 683, 251–258 (1996).Google Scholar
- 22.J. Rodriguez, G. Castaneda, and L. Munoz, J. Chromatogr. B, 913–914, 12–18 (2013).Google Scholar
- 25.S. Gomes, Int. J. Adv. Res. Pharm. Biosci., 3, 84–94 (2013).Google Scholar
- 27.J. J. Berzas, J. Rodriguez, A. M. Contento, and M. P. Cabello, J. Sep. Sci., 26, 908–914 (2003).Google Scholar
- 28.J. R. Flores, A. M. C. Salcedo, M. J. V. Llerena, and L. M. Fernandez, J. Chromatogr. A, 1185, 281–290 (2008).Google Scholar
- 32.M. R. Ganjali, A. Karimi, and P. Norouzi, Int. J. Electrochem. Sci., 7, 3681–3692 (2012).Google Scholar
- 33.H. P. Ranaganathan, G. Govindrajulu, and V. Palaniyappan, Int. J. Pharm. Pharm. Sci., 4, 582–586 (2012).Google Scholar
- 34.M. M. Annapurna, C. Mohapatro, and A. Narendo, J. Pharm. Anal., 2, 298–305 (2012).Google Scholar
- 35.E. F. Elkady and M. A. Fouad, Pak. J. Pharm. Sci., 28, 2041–2051 (2015).Google Scholar
- 36.ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology, Q2 (R1). Geneva (2005); http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1_Guideline.pdf. [Accessed 15 December 2016].